Literature DB >> 20570573

Characterization of macrophage activation states in patients with cystic fibrosis.

Brian S Murphy1, Heather M Bush, Vidya Sundareshan, Christina Davis, Jennifer Hagadone, Theodore J Cory, Heather Hoy, Don Hayes, Michael I Anstead, David J Feola.   

Abstract

BACKGROUND: Chronic airway inflammation characterizes patients with cystic fibrosis (CF). The role of alternative macrophage activation in this disease course is unknown.
OBJECTIVE: We evaluated markers of alternative and classical macrophage activation in the lungs of patients with CF and evaluated these characteristics in the context of Pseudomonas aeruginosa (PA) infection, immunomodulatory drug therapy and pulmonary function.
METHODS: Bronchoalveolar lavage or spontaneously expectorated sputum samples were collected from 48 CF patients. Clinical data were related to macrophage surface expression of mannose receptor (MR) (up-regulated in alternatively activated macrophages) and TLR4 (up-regulated in classically activated macrophages). Also, the activity of the alternatively activated macrophage effector molecule arginase was compared among patient groups, and pro- and anti-inflammatory cytokines produced by alternatively and classically activated macrophages were measured.
RESULTS: There were significant differences between PA-infected and -uninfected patients in several clinical measurements. PA-infected patients exhibited increased use of azithromycin, up-regulation of MR on CD11b+ cells and increased arginase activity in their lung samples, and had a strong inverse relationship between MR and arginase activity to FEV(1). Upon further analysis, PA-infected patients who were treated with azithromycin had the highest arginase activity and the highest number of macrophages that were MR+TLR4-, and both of these markers were inversely related to the FEV(1).
CONCLUSIONS: Our findings suggest an increase in both MR and arginase expression as pulmonary function declines in PA-infected patients with CF. These markers of an alternatively activated macrophage phenotype give cause for future study to define the function of macrophage activation states in the CF lung.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20570573     DOI: 10.1016/j.jcf.2010.04.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  34 in total

1.  Serum procalcitonin is not an early marker of pulmonary exacerbation in children with cystic fibrosis.

Authors:  Jacoba Johanna Louw; Jaan Toelen; Marijke Proesmans; François Vermeulen; Jaak Billen; Kris de Boeck
Journal:  Eur J Pediatr       Date:  2011-06-01       Impact factor: 3.183

2.  Down-regulation of IL-8 by high-dose vitamin D is specific to hyperinflammatory macrophages and involves mechanisms beyond up-regulation of DUSP1.

Authors:  N Dauletbaev; K Herscovitch; M Das; H Chen; J Bernier; E Matouk; J Bérubé; S Rousseau; L C Lands
Journal:  Br J Pharmacol       Date:  2015-10       Impact factor: 8.739

3.  A Flow Cytometric Method for Isolating Cystic Fibrosis Airway Macrophages from Expectorated Sputum.

Authors:  Katherine B Hisert; W Conrad Liles; Anne M Manicone
Journal:  Am J Respir Cell Mol Biol       Date:  2019-07       Impact factor: 6.914

4.  Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis.

Authors:  Theodore J Cory; Susan E Birket; Brian S Murphy; Don Hayes; Michael I Anstead; Jamshed F Kanga; Robert J Kuhn; Heather M Bush; David J Feola
Journal:  J Cyst Fibros       Date:  2013-09-07       Impact factor: 5.482

5.  Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1.

Authors:  Sarah A Ingersoll; Julie Laval; Osric A Forrest; Marcela Preininger; Milton R Brown; Dalia Arafat; Greg Gibson; Vin Tangpricha; Rabindra Tirouvanziam
Journal:  J Immunol       Date:  2015-04-29       Impact factor: 5.422

6.  Staphylococcus aureus Survives in Cystic Fibrosis Macrophages, Forming a Reservoir for Chronic Pneumonia.

Authors:  Cao Li; Yuqing Wu; Andrea Riehle; Jie Ma; Markus Kamler; Erich Gulbins; Heike Grassmé
Journal:  Infect Immun       Date:  2017-04-21       Impact factor: 3.441

7.  Burkholderia cenocepacia O polysaccharide chain contributes to caspase-1-dependent IL-1beta production in macrophages.

Authors:  Sheetal Kotrange; Benjamin Kopp; Anwari Akhter; Dalia Abdelaziz; Arwa Abu Khweek; Kyle Caution; Basant Abdulrahman; Mark D Wewers; Karen McCoy; Clay Marsh; Slade A Loutet; Ximena Ortega; Miguel A Valvano; Amal O Amer
Journal:  J Leukoc Biol       Date:  2010-12-22       Impact factor: 4.962

8.  Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.

Authors:  Preston E Bratcher; Steven M Rowe; Ginger Reeves; Tambra Roberts; Tomasz Szul; William T Harris; Rabindra Tirouvanziam; Amit Gaggar
Journal:  J Cyst Fibros       Date:  2015-03-11       Impact factor: 5.482

Review 9.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

10.  Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.

Authors:  Theodore J Cory; Susan E Birket; Brian S Murphy; Cynthia Mattingly; Jessica M Breslow-Deckman; David J Feola
Journal:  J Antimicrob Chemother       Date:  2012-12-17       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.